Antifungal use in immunocompetent, critically ill patients with pneumonia does not improve clinical outcomes

Heart Lung. 2016 Nov-Dec;45(6):538-543. doi: 10.1016/j.hrtlng.2016.08.002. Epub 2016 Sep 3.

Abstract

Purpose: To determine if treating bronchoalveolar lavage (BAL) culture-positive patients with antifungal therapy impacted mortality compared to not treating due to presumed colonization.

Methods: We conducted a retrospective study of immunocompetent, critically ill adult patients from 2010 to 2014. Patients with a BAL culture-positive for Candida or unspeciated yeast and a clinical suspicion of pneumonia were included. The treatment group received an antifungal agent for at least 5 days, and the control group received either no antifungal therapy or an antifungal agent for less than 48 h. Recruitment occurred in a 2:1 ratio of untreated versus treated patients.

Results: Seventy-five patients were included. In-hospital mortality was similar between treated and untreated groups (24% vs. 26%, P = 0.85). Length of stay and duration of mechanical ventilation also did not differ between the two groups.

Conclusion: We did not observe a difference in mortality or clinical outcomes in patients treated with antifungal agents. Presumptive antifungal therapy for BAL-positive Candida or yeast in immunocompetent patients did not result in improved clinical outcomes.

Keywords: Antifungal agents; Bronchoscopy; Candida; Pneumonia; Yeast.

MeSH terms

  • Adult
  • Antifungal Agents / therapeutic use*
  • Critical Illness*
  • Female
  • Hospital Mortality / trends
  • Humans
  • Immunocompromised Host*
  • Male
  • Middle Aged
  • Pneumonia, Ventilator-Associated / drug therapy*
  • Pneumonia, Ventilator-Associated / microbiology
  • Pneumonia, Ventilator-Associated / mortality
  • Prognosis
  • Respiration, Artificial / adverse effects
  • Retrospective Studies
  • United States / epidemiology

Substances

  • Antifungal Agents